2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome
artículo científico publicado en 2005
2008. Effective and Early Diagnosis of Pneumonia in Patients With Acute Leukemia in a Comprehensive Cancer Center: How Can We Improve the Microbiological Diagnosis?
6 Natural history and staging of chronic myelogenous leukaemia
⬇️
artículo científico publicado el 1 de junio de 1997
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
artículo científico publicado en 2004
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
artículo científico publicado en 2015
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
artículo científico publicado en 2017
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
artículo científico publicado en 2015
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
scientific article published on 02 August 2018
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
artículo científico publicado en 2016
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia
artículo científico publicado en 2004
A heavy metal baseline score predicts outcome in acute myeloid leukemia
journal article published in 2020
A journey searching for a cure for leukemia. Interviewed by Natasha Galukande
artículo científico publicado en 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia
artículo científico publicado en 2013
A multinational study of health state preference values associated with chronic myelogenous leukemia
artículo científico publicado en 2009
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
artículo científico publicado en 2008
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
artículo científico publicado en 2010
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
artículo científico publicado en 2014
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
artículo científico publicado en 2018
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
artículo científico publicado en 2013
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis
artículo científico publicado en 2013
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
artículo científico publicado en 2008
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generat
artículo científico publicado en 2015
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes
artículo científico publicado en 2002
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
artículo científico publicado en 2006
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
artículo científico publicado en 2017
A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.
artículo científico publicado en 2014
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
artículo científico publicado en 2016
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
artículo científico publicado en 2017
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia
artículo científico publicado en 2014
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
artículo científico publicado en 2008
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities
artículo científico publicado en 2012
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
artículo científico publicado en 2017
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
artículo científico publicado en 2007
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission
artículo científico publicado en 1999
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia
artículo científico publicado en 2014
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
artículo científico publicado en 2016
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
artículo científico publicado en 2018
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2017
A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.
artículo científico publicado en 2017
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
artículo científico publicado en 2011
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome
artículo científico publicado en 2011
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
artículo científico publicado en 2003
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens
artículo científico publicado en 2006
A second-generation TKI should always be used as initial therapy for CML
scholarly article published 26 December 2018
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
artículo científico publicado en 2003
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
artículo científico publicado en 2005
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
artículo científico publicado en 2005
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia
artículo científico publicado en 2011
Accelerated and blastic phases of chronic myelogenous leukemia
artículo científico publicado en 2004
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
artículo científico publicado en 2017
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
artículo científico publicado en 2012
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells
artículo científico publicado en 2006
Activity of alemtuzumab in patients with CD52-positive acute leukemia
scientific article published on 01 June 2006
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
artículo científico publicado en 2007
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis
artículo científico publicado en 2013
Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation
artículo científico publicado en 2015
Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation
artículo científico
Acute myeloid leukemia: advancing clinical trials and promising therapeutics
artículo científico publicado en 2016
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.
artículo científico publicado en 2012
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
artículo científico publicado en 2005
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
artículo científico publicado en 2003
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia
artículo científico publicado en 2018
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution
artículo científico publicado en 2009
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
artículo científico publicado en 2005
Advanced-phase chronic myeloid leukemia
artículo científico publicado en 2003
Advances in the therapy of chronic idiopathic myelofibrosis
artículo científico publicado en 2006
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation
artículo científico publicado en 2015
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
artículo científico publicado en 2003
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia
artículo científico publicado en 2009
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia
artículo científico publicado en 2017
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia
artículo científico publicado en 2016
Allogeneic hematopoietic cell transplant for prolymphocytic leukemia
⬇️
artículo científico publicado en 2009
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia
artículo científico publicado en 2012
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy
artículo científico publicado en 2014
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias
artículo científico publicado en 2011
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
artículo científico publicado en 2006
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
artículo científico publicado en 2003
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation
artículo científico publicado en 2007
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders
artículo científico publicado en 2003
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
artículo científico publicado en 2016
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
artículo científico publicado en 2012
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia
⬇️
artículo científico publicado el 1 de septiembre de 1997
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
artículo científico publicado en 2013
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
artículo científico publicado en 2017
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen
artículo científico publicado en 2010
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
artículo científico publicado en 2017
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy
artículo científico publicado en 2015
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
scientific article published on 01 December 2019
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months
artículo científico publicado en 2013
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial
artículo científico publicado en 2020
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
artículo científico publicado en 2018
Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome
artículo científico publicado en 2015
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
artículo científico publicado en 2014
Azacitidine for the treatment of myelodysplastic syndrome
artículo científico publicado en 2009
Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study
artículo científico publicado en 2012
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.
artículo científico publicado en 2015
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations
artículo científico publicado en 2008
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias
artículo científico publicado en 2008
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival
artículo científico publicado en 2015
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors
artículo científico publicado en 2009
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
scientific article published on March 2008
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia
artículo científico publicado en 2014
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein
artículo científico publicado en 2014
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study
scientific article published on 03 December 2020
Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia
artículo científico publicado en 2010
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
artículo científico publicado en 2013
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders
artículo científico publicado en 2004
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
artículo científico publicado en 2008
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia
artículo científico publicado en 2013
Biology of platelet-derived growth factor and its involvement in disease
artículo científico publicado en 2006
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
artículo científico publicado en 2009
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study
artículo científico publicado en 2007
Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value
artículo científico publicado en 2018
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival
artículo científico publicado en 2002
Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis
scientific article published on 23 January 2013
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome
artículo científico publicado en 2015
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
artículo científico publicado en 2017
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
artículo científico publicado en 2014
Bosutinib in the treatment of chronic myelogenous leukemia.
artículo científico publicado en 2012
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
scientific article published on 27 February 2012
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
artículo científico publicado en 2013
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
artículo científico publicado en 2014
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial
artículo científico publicado en 2012
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
scientific article published on 27 September 2016
Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
artículo científico publicado en 2011
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome
artículo científico publicado en 2004
CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias
artículo científico publicado en 2013
CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis
artículo científico publicado en 2013
CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes
artículo científico publicado en 2013
CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count
artículo científico publicado en 2016
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia
artículo científico publicado en 2002
CML: the good, the better, and the difficult choices.
artículo científico publicado en 2012
CMML: a biologically distinct myeloproliferative disease.
artículo científico publicado en 2003
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
scientific article published on 19 July 2018
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System
artículo científico publicado en 2015
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations
artículo científico publicado en 2013
Cause of death in patients with lower-risk myelodysplastic syndrome
artículo científico publicado en 2010
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies
artículo científico publicado en 2010
Central nervous system relapse in adults with acute lymphoblastic leukemia
artículo científico publicado en 2002
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations
artículo científico publicado en 2018
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
artículo científico publicado en 2008
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
artículo científico publicado en 2010
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach
artículo científico publicado en 2017
Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
artículo científico publicado en 2012
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
artículo científico publicado en 2008
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia
artículo científico publicado en 2014
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment
artículo científico publicado en 2009
Characteristics of Sweet Syndrome in patients with acute myeloid leukemia
artículo científico publicado en 2014
Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy
artículo científico publicado en 2019
Characteristics of pericardial effusions in patients with leukemia
artículo científico publicado en 2010
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia
artículo científico publicado en 2012
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
artículo científico publicado en 2015
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
artículo científico publicado en 2017
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
artículo científico publicado en 2010
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
artículo científico publicado en 2005
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
artículo científico publicado en 2006
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage
scientific article published on 11 October 2018
Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents
artículo científico publicado en 2002
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
scientific article published on 20 August 2019
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
artículo científico publicado en 2007
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
artículo científico publicado en 2003
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis
artículo científico publicado en 2015
Chromosome 5q deletion is extremely rare in patients with myelofibrosis
artículo científico publicado en 2013
Chronic myelogenous leukemia: a review and update of therapeutic strategies
artículo científico publicado en 2003
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
artículo científico publicado en 2009
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship
artículo científico publicado en 2016
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
artículo científico publicado en 2010
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature
artículo científico publicado en 2004
Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature
artículo científico
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?
artículo científico publicado en 2010
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
scientific article published on September 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
artículo científico publicado en 2009
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment
artículo científico publicado en 2005
Chronic myeloid leukemia: diagnosis and treatment
artículo científico publicado en 2006
Chronic myeloid leukemia: mechanisms of resistance and treatment
artículo científico publicado en 2011
Chronic myeloid leukemia: overview of new agents and comparative analysis
artículo científico
Chronic myeloid leukemia: reminiscences and dreams
artículo científico publicado en 2016
Chronic myeloid leukemia: sequencing of TKI therapies.
artículo científico publicado en 2016
Chronic myeloid leukemia: the race is yet to be won.
artículo científico publicado en 2012
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia
artículo científico publicado en 2008
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
scientific article published on 13 August 2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
artículo científico publicado en 2018
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia
scientific article published on 13 May 2019
Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies
artículo científico publicado en 2017
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
artículo científico publicado en 2017
Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience
artículo científico
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction
artículo científico publicado en 2015
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action
artículo científico publicado en 2004
Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts
artículo científico publicado en 2013
Clinical activity of tipifarnib in hematologic malignancies
artículo científico publicado en 2007
Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
artículo científico publicado en 2017
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
artículo científico publicado en 2015
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.
artículo científico publicado en 2017
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.
artículo científico publicado en 2012
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
scientific article published on 29 October 2020
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis
artículo científico publicado en 2014
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens
artículo científico publicado en 2017
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia
scientific article published on 29 July 2013
Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).
artículo científico publicado en 2016
Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome
artículo científico publicado en 2002
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
artículo científico publicado en 2017
Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
artículo científico publicado en 2014
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.
artículo científico publicado en 2012
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
artículo científico publicado en 2010
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
artículo científico publicado en 2016
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
scientific article published in Nature Communications
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
artículo científico publicado en 2012
Clinical significance of microcytosis in patients with primary myelofibrosis
artículo científico publicado en 2014
Clinical trials have a home in Blood
artículo científico publicado en 2014
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study
artículo científico publicado en 2016
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients
artículo científico publicado en 2015
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
artículo científico publicado en 2006
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation
artículo científico publicado en 2012
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2013
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment
artículo científico publicado en 2017
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
artículo científico publicado en 2017
Clonal evolution in chronic myelogenous leukemia
artículo científico publicado en 2004
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
artículo científico publicado en 2020
Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group
artículo científico publicado en 2017
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia
artículo científico publicado en 2020
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
artículo científico publicado en 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
scientific article published on 01 December 2018
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
artículo científico publicado en 2016
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation
artículo científico publicado en 2014
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis
artículo científico publicado en 2011
Competing cell clones in myeloproliferative neoplasm
artículo científico publicado en 2010
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
artículo científico publicado en 2003
Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.
artículo científico publicado en 2014
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia
artículo científico publicado en 2009
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
artículo científico publicado en 2015
Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
artículo científico publicado en 2021
Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
artículo científico publicado en 2017
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
artículo científico publicado en 2015
Congestive heart failure is a rare event in patients receiving imatinib therapy
artículo científico publicado en 2007
Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
artículo científico publicado en 2011
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia
scientific article published on 25 November 2019
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study
scientific article published on 16 August 2010
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
artículo científico publicado en 2015
Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study
artículo científico publicado en 2013
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].
artículo científico publicado en 2017
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
artículo científico publicado en 2013
Current and emerging treatment options in chronic myeloid leukemia
artículo científico publicado en 2007
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia
artículo científico publicado en 2010
Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure
artículo científico publicado en 2012
Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET).
artículo científico publicado en 2010
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment
artículo científico publicado en 2007
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia
artículo científico publicado en 2001
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
artículo científico publicado en 2009
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
artículo científico publicado en 2008
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
artículo científico publicado en 2017
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia
artículo científico publicado en 2010
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
artículo científico publicado en 2010
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
artículo científico publicado en 2009
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias
artículo científico publicado en 2007
Dasatinib for the treatment of Philadelphia chromosome-positive leukemias
artículo científico
Dasatinib for the treatment of chronic myeloid leukemia
artículo científico publicado en 2011
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
artículo científico publicado en 2006
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
artículo científico publicado en 2016
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily
artículo científico publicado en 2010
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
artículo científico publicado en 2009
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
artículo científico publicado en 2006
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
artículo científico publicado en 2011
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations
scientific article published on April 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
scientific article published on 24 September 2009
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
artículo científico publicado en 2010
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase
artículo científico publicado en 2011
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome
artículo científico publicado en 2013
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
⬇️
artículo científico publicado el 24 de agosto de 2010
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
scientific article published on 15 April 2009
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
artículo científico publicado en 2018
Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia
artículo científico publicado en 2013
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes
artículo científico publicado en 2015
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
artículo científico publicado en 2013
Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission
artículo científico publicado en 2013
Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis
artículo científico publicado en 2012
Determination of Fitness and Therapeutic Options in Older Patients With Acute Myeloid Leukemia
artículo científico publicado en 2020
Development and targeted use of nilotinib in chronic myeloid leukemia.
artículo científico publicado en 2009
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study
artículo científico publicado en 2019
Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.
artículo científico
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns
artículo científico publicado en 2007
Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
scientific article published on 06 May 2016
Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia
artículo científico publicado en 2017
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
artículo científico publicado en 2016
Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia
artículo científico publicado en 2012
Discontinuation of imatinib therapy after achieving a molecular response
artículo científico publicado en 2004
Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers
artículo científico publicado en 2013
Disruption of Wnt/β-catenin exerts anti-leukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia
artículo científico publicado en 2018
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
artículo científico publicado en 2011
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?
artículo científico publicado en 2013
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
artículo científico publicado en 2017
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
artículo científico publicado en 2002
Double-hit of FLT3 gene in a fatal case of acute myemonocytic leukaemia
artículo científico publicado en 2013
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
artículo científico publicado en 2007
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
artículo científico publicado en 2009
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
artículo científico publicado en 2009
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
artículo científico publicado en 2014
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
artículo científico publicado en 2011
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
artículo científico publicado en 2012
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
artículo científico publicado en 2006
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
artículo científico publicado en 2016
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
artículo científico publicado en 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
artículo científico publicado en 2013
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
artículo científico publicado en 2005
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
artículo científico publicado en 2018
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy
artículo científico publicado en 2013
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
artículo científico publicado en 2003
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
artículo científico publicado en 2015
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
artículo científico publicado en 2008
Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies
artículo científico
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit
artículo científico publicado en 2006
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias
artículo científico
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
artículo científico publicado en 2003
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
artículo científico publicado en 2008
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
artículo científico publicado en 2019
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome
artículo científico publicado en 2009
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
artículo científico publicado en 2019
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
artículo científico publicado en 2009
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome
artículo científico publicado en 2003
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
artículo científico publicado en 2002
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
artículo científico publicado en 2018
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
⬇️
artículo científico publicado el 22 de marzo de 2011
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors
artículo científico publicado en 2007
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
artículo científico publicado en 2003
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
artículo científico publicado en 2009
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2012
Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia
artículo científico publicado en 2012
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial
scientific article published on 12 July 2011
Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine
artículo científico publicado en 2012
Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
scholarly article published in Cancer
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase
artículo científico publicado en 2004
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia
artículo científico
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
artículo científico publicado en 2015
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
artículo científico publicado en 2012
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
artículo científico publicado en 2013
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study
artículo científico publicado en 2016
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
artículo científico publicado en 2011
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
artículo científico publicado en 2017
Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia
artículo científico publicado en 2007
Evolution of therapies for chronic myelogenous leukemia
artículo científico publicado en 2011
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
artículo científico publicado en 2006
Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy
artículo científico publicado en 2013
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
artículo científico publicado en 2003
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis
artículo científico publicado en 2010
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia
artículo científico publicado en 2002
Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia
artículo científico publicado en 2011
Experimental therapeutics for patients with myeloproliferative neoplasias
artículo científico publicado en 2010
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
artículo científico publicado en 2013
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
artículo científico publicado en 2011
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
artículo científico publicado en 2012
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
artículo científico publicado en 2007
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia
artículo científico publicado en 2017
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
artículo científico publicado en 2015
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast
artículo científico publicado en 2009
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
artículo científico publicado en 2008
Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome.
artículo científico publicado en 2004
Farnesyl transferase inhibitor resistance probed by target mutagenesis
artículo científico publicado en 2007
Farnesyltransferase Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndromes
⬇️
artículo científico publicado el 1 de agosto de 2003
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
artículo científico publicado en 2003
Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies
artículo científico publicado en 2002
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment
artículo científico publicado en 2007
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency
artículo científico publicado en 2010
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
artículo científico publicado en 2016
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up
artículo científico publicado en 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
artículo científico publicado en 2015
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia
artículo científico publicado en 2014
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2015
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
artículo científico publicado en 2018
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen
artículo científico publicado en 2016
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
artículo científico publicado en 2010
First-line therapy for chronic myeloid leukemia: Past, present, and future
artículo científico publicado en 2009
First-line treatment for patients with CML in chronic phase: second-generation TKIs are the therapy of choice
artículo científico publicado en 2013
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
artículo científico publicado en 2017
Flying under the radar: the new wave of BCR-ABL inhibitors
artículo científico publicado en 2007
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit
artículo científico publicado en 2003
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia
artículo científico publicado en 2011
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
artículo científico publicado en 2011
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis
artículo científico publicado en 2016
Frontline treatment of acute myeloid leukemia in adults
artículo científico publicado en 2016
Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies
artículo científico publicado en 2002
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia
artículo científico publicado en 2014
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi
artículo científico publicado en 2002
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
artículo científico publicado en 2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
artículo científico publicado en 2003
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
scientific article published on 01 October 2019
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
artículo científico publicado en 2018
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials
artículo científico publicado en 2019
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia
artículo científico publicado en 2004
Granulocytic sarcoma of the pancreas: a report of two cases and literature review
artículo científico publicado en 1999
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia
artículo científico publicado en 2013
Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
artículo científico publicado en 2017
Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
artículo científico publicado en 2016
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
artículo científico publicado en 2010
Hedgehog signaling inhibitors in solid and hematological cancers
artículo científico publicado en 2019
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
artículo científico publicado en 2010
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
artículo científico publicado en 2009
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
artículo científico publicado en 2003
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
artículo científico publicado en 2017
Homoharringtonine for the treatment of chronic myelogenous leukemia
artículo científico publicado en 2008
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
artículo científico publicado en 2009
Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval
scientific article published on 20 June 2013
How I treat newly diagnosed chronic phase CML
artículo científico publicado en 2012
How to manage CML patients with comorbidities?
artículo científico publicado en 2020
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
artículo científico publicado en 2010
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma
artículo científico publicado en 2017
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis
artículo científico publicado en 2016
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia
artículo científico publicado en 2002
Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients
artículo científico publicado en 2011
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
artículo científico publicado en 2015
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
artículo científico publicado en 2019
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
artículo científico publicado en 2009
Imatinib effect on growth and signal transduction in polycythemia vera
artículo científico publicado en 2007
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction
artículo científico publicado en 2010
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status
artículo científico publicado en 2008
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
artículo científico publicado en 2002
Imatinib mesylate causes hypopigmentation in the skin
artículo científico publicado en 2003
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
artículo científico publicado en 2008
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
artículo científico publicado en 2002
Imatinib mesylate in the treatment of chronic myelogenous leukemia
artículo científico publicado en 2004
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001
artículo científico publicado en 2009
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
artículo científico publicado en 2002
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
artículo científico publicado en 2003
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
artículo científico publicado en 2002
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
artículo científico publicado en 2004
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
artículo científico publicado en 2004
Imatinib therapy for chronic myeloid leukemia: where do we go now?
artículo científico publicado en 2008
Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors
artículo científico publicado en 2007
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin
artículo científico publicado en 2010
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
artículo científico publicado en 2016
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
artículo científico publicado en 2017
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
artículo científico publicado en 2009
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
artículo científico publicado en 2016
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).
artículo científico publicado en 2013
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
artículo científico publicado en 2016
Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia
artículo científico publicado en 2012
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2019
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia
artículo científico publicado en 2011
Important therapeutic targets in chronic myelogenous leukemia
artículo científico publicado en 2007
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
artículo científico publicado en 2012
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade
artículo científico publicado en 2015
Improving attribution of adverse events in oncology clinical trials
artículo científico publicado en 2019
Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience
artículo científico publicado en 2014
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
scientific article published on 23 July 2015
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
artículo científico publicado en 2007
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
artículo científico publicado en 2015
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia
artículo científico publicado en 2014
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience
artículo científico publicado en 2009
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
artículo científico publicado en 2019
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide
artículo científico publicado en 2014
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
scholarly article by Timothy P Hughes et al published January 2019 in Haematologica
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
artículo científico publicado en 2003
Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities
artículo científico publicado en 2015
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia
artículo científico publicado en 2003
Influence of IDH on FLT3-ITD status in newly diagnosed AML.
artículo científico publicado en 2017
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells
artículo científico publicado en 2009
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
⬇️
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl
scientific article published on 15 April 2019
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
artículo científico publicado en 2012
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
artículo científico publicado en 2015
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes
artículo científico publicado en 2018
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
artículo científico publicado en 2010
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts
scientific article published on 29 April 2019
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study
artículo científico publicado en 2010
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
artículo científico publicado en 2016
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986
artículo científico publicado en 2005
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia
artículo científico publicado en 2004
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
artículo científico publicado en 2006
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications
scientific article published on 04 October 2010
Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions
artículo científico publicado en 2003
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy
artículo científico publicado en 2004
Introduction to a review series on adolescent and young adult malignant hematology
artículo científico publicado en 2018
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
artículo científico publicado en 2014
Investigational agents in myeloid disorders
artículo científico publicado en 2004
Investigational strategies in chronic myelogenous leukemia
artículo científico publicado en 2004
Is acute myeloid leukemia a liquid tumor?
artículo científico publicado en 2013
Is there a standard induction regimen for patients with AML?
artículo científico publicado en 2013
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms
artículo científico publicado en 2013
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia
scientific article published on 27 February 2019
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
artículo científico publicado en 2011
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival
artículo científico publicado en 2015
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
artículo científico publicado en 2016
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors
artículo científico publicado en 2013
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
artículo científico publicado en 2008
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents
artículo científico publicado en 2014
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome
artículo científico publicado en 2010
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
scientific article published on 17 June 2019
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis
artículo científico publicado en 2009
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
artículo científico publicado en 2006
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting
artículo científico publicado en 2017
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.
artículo científico publicado en 2018
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome
artículo científico publicado en 2003
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
artículo científico publicado en 2016
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
artículo científico publicado en 2018
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
artículo científico publicado en 2015
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
scholarly article by Oliver Ottmann et al published 3 September 2018 in Blood Cancer Journal
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib
artículo científico publicado en 2016
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
artículo científico publicado en 2015
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
scientific article published on 25 September 2019
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody
artículo científico publicado en 2012
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
artículo científico publicado en 2006
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr
artículo científico publicado en 2015
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
artículo científico publicado en 2016
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
artículo científico publicado en 2009
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
artículo científico publicado en 2014
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors
artículo científico publicado en 2010
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
artículo científico publicado en 2012
Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
artículo científico publicado en 2017
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib
artículo científico publicado en 2010
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st
artículo científico publicado en 2014
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia
artículo científico publicado en 2020
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis
artículo científico publicado en 2016
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
artículo científico publicado en 2014
Long-term results of frontline dasatinib in chronic myeloid leukemia
scientific article published on 30 January 2020
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
scientific article published on 14 April 2008
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha
artículo científico publicado en 2004
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia
artículo científico publicado en 2014
Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience
artículo científico publicado en 2005
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
artículo científico publicado en 2016
MYC protein expression is an important prognostic factor in acute myeloid leukemia
artículo científico publicado en 2018
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
artículo científico publicado en 2011
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes
artículo científico publicado en 2016
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
scholarly article by Jorge Eduardo Cortes et al published 27 December 2018 in Journal of Hematology & Oncology
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience
scientific article published on 07 December 2020
Management of imatinib-resistant patients with chronic myeloid leukemia
artículo científico publicado en 2013
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
artículo científico publicado en 2007
Management of patients with resistant or refractory chronic myelogenous leukemia.
artículo científico publicado en 2008
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience
artículo científico publicado en 2004
Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome
artículo científico publicado en 2017
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia
scientific article published on 15 May 2019
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
artículo científico publicado en 2013
Measuring the symptom burden associated with the treatment of chronic myeloid leukemia
artículo científico publicado en 2013
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia
artículo científico publicado en 2011
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia
artículo científico publicado en 2009
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
artículo científico publicado en 2011
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
artículo científico publicado en 2015
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia
artículo científico publicado en 2017
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia
artículo científico publicado en 2003
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia
artículo científico publicado en 2013
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
artículo científico publicado en 2013
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations
artículo científico publicado en 2008
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
artículo científico publicado en 2008
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications
artículo científico publicado en 2008
Molecular resistance: an early indicator for treatment change?
artículo científico
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
artículo científico publicado en 2005
Molecular targeted therapy in acute myeloid leukemia
artículo científico publicado en 2012
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
artículo científico publicado en 2006
Monitoring molecular response in chronic myeloid leukemia
⬇️
artículo científico publicado el 19 de octubre de 2010
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
artículo científico publicado en 2007
More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.
artículo científico publicado en 2017
Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia
artículo científico publicado en 2016
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia
artículo científico publicado en 2011
Mutant BCR-ABL clones in chronic myeloid leukemia
artículo científico publicado en 2011
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia
artículo científico publicado en 2008
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse
artículo científico publicado en 2013
Mutations in AML: prognostic and therapeutic implications
artículo científico publicado en 2016
Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome
artículo científico publicado en 2000
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
artículo científico publicado en 2006
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor
artículo científico publicado en 2014
Myelopathy following intrathecal chemotherapy in adults: a single institution experience
artículo científico publicado en 2015
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
artículo científico publicado en 2002
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
artículo científico publicado en 2003
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia
artículo científico publicado en 2019
Natural history and staging of chronic myelogenous leukemia
artículo científico publicado en 2004
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents
artículo científico publicado en 2017
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series
artículo científico publicado en 2019
Neutrophilic-chronic myeloid leukemia
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course
artículo científico publicado en 2002
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia
artículo científico publicado en 2017
New agents in acute myeloid leukemia and other myeloid disorders
artículo científico publicado en 2004
New agents in chronic myelogenous leukemia.
artículo científico publicado en 2003
New agents in the treatment of acute lymphocytic leukaemia
artículo científico publicado en 2002
New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia
artículo científico publicado en 2007
New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia
scientific article published on February 2011
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
artículo científico publicado en 2006
New strategies in chronic myeloid leukemia
artículo científico publicado en 2006
New targeted approaches in chronic myeloid leukemia
artículo científico publicado en 2005
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance
artículo científico publicado en 2007
New treatment for acute myelogenous leukemia
artículo científico publicado en 2014
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring
artículo científico publicado en 2013
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
artículo científico publicado en 2007
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
artículo científico publicado en 2009
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia
⬇️
artículo científico publicado el 13 de noviembre de 2010
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
⬇️
artículo científico publicado el 15 de junio de 2010
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
artículo científico publicado en 2006
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
artículo científico publicado en 2011
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
artículo científico publicado en 2010
Nilotinib therapy in chronic myelogenous leukemia
artículo científico publicado en 2007
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias
artículo científico publicado en 2008
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases
scientific article published on October 2008
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
scientific article published on 15 April 2004
Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia.
artículo científico publicado en 2011
Novel approaches in the treatment of systemic mastocytosis
artículo científico publicado en 2006
Novel therapies for patients with chronic myeloid leukemia
artículo científico publicado en 2004
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity
scientific article published on 01 July 2007
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia
artículo científico publicado en 2006
Obesity, weight gain, and risk of chronic myeloid leukemia
artículo científico publicado en 2009
Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia
artículo científico publicado en 2012
Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia
artículo científico publicado en 2016
Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia
artículo científico publicado en 2013
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
artículo científico publicado en 2013
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors
artículo científico publicado en 2014
Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
artículo científico publicado en 2008
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia
artículo científico publicado en 2014
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies
artículo científico publicado en 2006
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
artículo científico publicado en 2007
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase
artículo científico publicado en 2007
Optimizing first-line therapy for patients with chronic myeloid leukemia.
artículo científico publicado en 2009
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
artículo científico publicado en 2013
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia
artículo científico publicado en 2008
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase
artículo científico publicado en 2010
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
artículo científico publicado en 2010
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia
artículo científico publicado en 2013
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy
artículo científico publicado en 2003
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia
artículo científico publicado en 2016
Outcome of adults with acute lymphocytic leukemia after second salvage therapy
artículo científico publicado en 2008
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission
artículo científico publicado en 2010
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
artículo científico publicado en 2009
Outcome of patients with acute myelogenous leukemia after second salvage therapy
artículo científico publicado en 2005
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy
artículo científico publicado en 2011
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
artículo científico publicado en 2010
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
artículo científico publicado en 2017
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy
artículo científico publicado en 2010
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure
artículo científico publicado en 2011
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
artículo científico publicado en 2004
Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation
artículo científico publicado en 2013
Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia
artículo científico publicado en 2017
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy
scientific article published on 28 February 2020
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma
artículo científico publicado en 2017
Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens
artículo científico publicado en 2014
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy
artículo científico publicado en 2019
Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure
artículo científico publicado en 2014
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
artículo científico publicado en 2018
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
scientific article published on 08 October 2020
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation
artículo científico publicado en 2017
Overcoming drug resistance in chronic myeloid leukemia
artículo científico publicado en 2006
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study
artículo científico publicado en 2007
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
artículo científico publicado en 2013
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
artículo científico publicado en 2016
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
artículo científico publicado en 2007
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
artículo científico publicado en 2016
Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms
artículo científico publicado en 2017
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
artículo científico publicado en 2013
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
scientific article published on 15 April 2019
Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome
artículo científico publicado en 2013
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
artículo científico publicado en 2017
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia
artículo científico publicado en 2011
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
artículo científico publicado en 2017
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
artículo científico publicado en 2009
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy
artículo científico publicado en 2016
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation
artículo científico publicado en 2011
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia
artículo científico publicado en 2016
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
artículo científico publicado en 2016
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial
artículo científico publicado en 2005
Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia
artículo científico publicado en 2015
Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients
artículo científico publicado en 2020
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
artículo científico publicado en 2016
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
artículo científico publicado en 2005
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance
artículo científico publicado en 2010
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies
artículo científico publicado en 2008
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
artículo científico publicado en 2012
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies
artículo científico publicado en 2003
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
artículo científico publicado en 2017
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
artículo científico publicado en 2007
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
artículo científico publicado en 2008
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
artículo científico publicado en 2007
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
artículo científico publicado en 2006
Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
artículo científico publicado en 2020
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
artículo científico publicado en 2003
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
artículo científico publicado en 2011
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
artículo científico publicado en 2009
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
artículo científico publicado en 2013
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
artículo científico publicado en 2012
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
artículo científico publicado en 2013
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
artículo científico publicado en 2012
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
artículo científico publicado en 2014
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
scholarly article by Farhad Ravandi et al published November 2018 in Haematologica
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
artículo científico publicado en 2009
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia
artículo científico publicado en 2013
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
artículo científico publicado en 2003
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
artículo científico publicado en 2002
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
artículo científico publicado en 2004
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome
artículo científico publicado en 2009
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
artículo científico publicado en 2003
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
artículo científico publicado en 2013
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia
artículo científico publicado en 2005
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
artículo científico publicado en 2018
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes
artículo científico publicado en 2005
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies
artículo científico publicado en 2015
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome
artículo científico publicado en 2008
Phase I study of bortezomib in refractory or relapsed acute leukemias
artículo científico publicado en 2004
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
artículo científico publicado en 2005
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia
artículo científico publicado en 2016
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status
artículo científico publicado en 2013
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
artículo científico publicado en 2010
Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome
artículo científico publicado en 2012
Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia
artículo científico publicado en 2020
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
artículo científico publicado en 2010
Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
artículo científico publicado en 2016
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
artículo científico publicado en 2007
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
artículo científico publicado en 2015
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
artículo científico publicado en 2015
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
scientific article published on 20 December 2018
Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
artículo científico publicado en 2015
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
artículo científico publicado en 2004
Phase II study of alemtuzumab in chronic lymphoproliferative disorders
artículo científico publicado en 2003
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
artículo científico publicado en 2008
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders
artículo científico publicado en 2002
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
artículo científico publicado en 2009
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
artículo científico publicado en 2007
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate
artículo científico publicado en 2005
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia
artículo científico publicado en 2014
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia
artículo científico publicado en 2014
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
artículo científico publicado en 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
artículo científico publicado en 2003
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
artículo científico publicado en 2020
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia
artículo científico publicado en 2017
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia
artículo científico publicado en 2014
Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
artículo científico publicado en 2015
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome
artículo científico publicado en 2012
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
artículo científico publicado en 2014
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose c
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati
artículo científico publicado en 2009
Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in Combination With Standard Chemotherapy in Patients With AML or High-Risk MDS.
artículo científico publicado en 2018
Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia
scientific article published on 28 July 2019
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors
artículo científico publicado en 2019
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia
artículo científico publicado en 2008
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy
artículo científico publicado en 2007
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
artículo científico publicado en 2002
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase
artículo científico publicado en 2011
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
artículo científico publicado en 2003
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy
artículo científico publicado en 2006
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia
artículo científico publicado en 2002
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
artículo científico publicado en 2012
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management
artículo científico publicado en 2016
Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure
article
Pneumonia during remission induction chemotherapy in patients with acute leukemia
artículo científico publicado en 2013
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study
artículo científico publicado en 2015
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
artículo científico publicado en 2018
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study
artículo científico publicado en 2013
Ponatinib in refractory Philadelphia chromosome-positive leukemias
artículo científico publicado en 2012
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
artículo científico publicado en 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor
artículo científico publicado en 2016
Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid
artículo científico publicado en 2005
Potential role of sorafenib in the treatment of acute myeloid leukemia
artículo científico publicado en 2008
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
artículo científico publicado en 2010
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia
artículo científico
Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy
artículo científico publicado en 2014
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
artículo científico publicado en 2017
Prediction model for mortality after intracranial hemorrhage in patients with leukemia
artículo científico publicado en 2011
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
artículo científico publicado en 2011
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
artículo científico publicado en 2003
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
artículo científico publicado en 2010
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome
artículo científico publicado en 2010
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance
artículo científico publicado en 2009
Pregnancy among patients with chronic myeloid leukemia treated with imatinib
artículo científico publicado en 2006
Pregnancy in a patient with hypereosinophilic syndrome
artículo científico publicado en 2008
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
artículo científico publicado en 2020
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System
artículo científico publicado en 2007
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients
artículo científico publicado en 2017
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine
artículo científico publicado en 2012
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody
artículo científico publicado en 2015
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome
artículo científico publicado en 2013
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
artículo científico publicado en 2020
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib
artículo científico publicado en 2011
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia
artículo científico publicado en 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease
artículo científico publicado en 2016
Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis
artículo científico publicado en 2013
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics
artículo científico publicado en 2014
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia
artículo científico publicado en 2013
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia
artículo científico publicado en 2007
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation
artículo científico publicado en 2012
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
artículo científico publicado en 2008
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors
artículo científico publicado en 2017
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin
artículo científico publicado en 2011
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib
artículo científico publicado en 2019
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
artículo científico publicado en 2003
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
artículo científico publicado en 2016
Prognostic significance of hyperdiploidy in adult acute myeloid leukemia
artículo científico publicado en 2018
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia
artículo científico publicado en 2015
Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia
artículo científico publicado en 2010
Progress in acute myeloid leukemia
artículo científico publicado en 2015
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
artículo científico publicado en 2008
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome
artículo científico publicado en 2009
Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia
artículo científico publicado en 2016
Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells
artículo científico publicado en 2013
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
artículo científico publicado en 2020
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
artículo científico publicado en 2003
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
scientific article published on 04 June 2019
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
artículo científico publicado en 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
artículo científico publicado en 2018
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
artículo científico publicado en 2003
Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients
artículo científico publicado en 2010
Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays
artículo científico publicado en 2010
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia
artículo científico publicado en 2008
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis
scientific article published on 26 March 2019
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation
artículo científico publicado en 2017
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
artículo científico publicado en 2015
Reply to K.R. Hoffman
scientific article published on 14 November 2016
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options
artículo científico publicado en 2013
Response kinetics and factors predicting survival in core-binding factor leukemia
artículo científico publicado en 2018
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate
artículo científico publicado en 2002
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha
artículo científico publicado en 2003
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib
artículo científico publicado en 2007
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
artículo científico publicado en 2004
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
artículo científico publicado en 2006
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
artículo científico publicado en 2010
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
artículo científico publicado en 2009
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
artículo científico publicado en 2003
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
artículo científico publicado en 2004
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
artículo científico publicado en 2003
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
artículo científico publicado en 2013
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
artículo científico publicado en 2014
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
artículo científico publicado en 2018
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
artículo científico publicado en 2001
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
artículo científico publicado en 2003
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine
artículo científico publicado en 2013
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies
artículo científico publicado en 2014
Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment
artículo científico publicado en 2012
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
scientific article published on 22 March 2016
Rituximab in relapsed or refractory hairy cell leukemia
artículo científico publicado en 2003
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia
scientific article published on September 2011
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
scientific article published on 18 June 2015
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia
artículo científico publicado en 2014
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
artículo científico publicado en 2003
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
artículo científico publicado en 2017
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial
artículo científico
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
artículo científico publicado en 2010
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
artículo científico publicado en 2011
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
artículo científico publicado en 2011
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.
artículo científico publicado en 2018
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial
artículo científico publicado en 2018
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
artículo científico publicado en 2014
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
artículo científico publicado en 2017
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD
artículo científico publicado en 2013
Saving Medicare through patient-centered changes--the case of injectables
artículo científico publicado en 2013
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
artículo científico publicado en 2016
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
scientific article published on May 2007
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy
scientific article published on 09 February 2011
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
artículo científico publicado en 2008
Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience
artículo científico publicado en 2015
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review
scientific article published on 24 September 2020
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia
artículo científico publicado en 2013
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
artículo científico publicado en 2017
Sepsis and Acute Myeloid Leukemia: A Population-Level Study of Comparative Outcomes of Patients Discharged From Texas Hospitals
artículo científico
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
scientific article published on 22 December 2014
Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse
artículo científico publicado en 2009
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
artículo científico publicado en 2013
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response
artículo científico publicado en 2009
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
artículo científico publicado en 2005
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission
artículo científico publicado en 2017
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
artículo científico publicado en 2009
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications
artículo científico publicado en 2011
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
artículo científico publicado en 2017
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials
artículo científico publicado en 2013
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia
artículo científico publicado en 2002
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
artículo científico publicado en 2003
Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data
artículo científico publicado en 2013
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells
artículo científico publicado en 2015
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
scientific article published on 31 August 2018
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia
scientific article published on 16 July 2019
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation
artículo científico publicado en 2013
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal
artículo científico publicado en 2006
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
artículo científico publicado en 2010
Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation
artículo científico publicado en 2006
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib
artículo científico publicado en 2013
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
scientific article published on February 2009
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
artículo científico publicado en 2005
Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia
artículo científico publicado en 2019
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications
artículo científico publicado en 2003
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities
artículo científico publicado en 2009
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience
artículo científico publicado en 2007
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
artículo científico publicado en 2004
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience
artículo científico publicado en 2005
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia
artículo científico publicado en 2009
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
artículo científico publicado en 2020
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy
artículo científico publicado en 2010
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML
artículo científico publicado en 2012
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years
artículo científico publicado en 2020
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha
artículo científico publicado en 2008
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials
artículo científico publicado en 2009
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
artículo científico publicado en 2016
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
artículo científico publicado en 2015
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial
artículo científico publicado en 2009
Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia
artículo científico publicado en 2017
T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1.
artículo científico publicado en 2009
T-cell prolymphocytic leukemia: a single-institution experience
scientific article published on 01 November 2005
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens
artículo científico publicado en 2017
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
artículo científico publicado en 2016
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones
artículo científico publicado en 2008
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide
artículo científico publicado en 2015
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia
artículo científico publicado en 2013
Targeted therapy in chronic myeloid leukemia
artículo científico publicado en 2008
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib
artículo científico publicado en 2006
Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
artículo científico publicado en 2015
Targeting neuropilin-1 in human leukemia and lymphoma
artículo científico publicado en 2011
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia
artículo científico publicado en 2005
Thalidomide therapy for myelofibrosis with myeloid metaplasia
scientific article published on 01 May 2006
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
artículo científico publicado en 2013
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis
artículo científico publicado en 2013
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation
artículo científico publicado en 2008
The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes
artículo científico publicado en 2020
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling
artículo científico publicado en 2014
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
scientific article published on 01 October 2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
artículo científico publicado en 2016
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab
artículo científico publicado en 2017
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure
artículo científico publicado en 2013
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
artículo científico publicado en 2011
The biology of chronic myelogenous leukemia: implications for imatinib therapy
artículo científico publicado en 2007
The changing face of acute myeloid leukemia therapeutics in the elderly population
artículo científico publicado en 2015
The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
artículo científico publicado en 2013
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
artículo científico publicado en 2011
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy
artículo científico publicado en 2005
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
artículo científico publicado en 2018
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival
scientific article published on 19 November 2019
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes
artículo científico publicado en 2014
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
artículo científico publicado en 2008
The effects of imatinib on pregnancy outcome
artículo científico publicado en 2008
The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
artículo científico publicado en 2010
The impact of dasatinib on pregnancy outcomes
artículo científico publicado en 2015
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
artículo científico publicado en 2008
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
artículo científico publicado en 2013
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells
artículo científico publicado en 2007
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients
artículo científico publicado en 2008
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors
artículo científico publicado en 2006
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
artículo científico publicado en 2009
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma
artículo científico publicado en 2002
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia
artículo científico
The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era
artículo científico publicado en 2011
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
artículo científico publicado en 2004
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
scientific article published on 03 September 2009
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia
⬇️
artículo científico publicado el 15 de septiembre de 1995
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years
artículo científico publicado en 2008
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
artículo científico publicado en 2015
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
artículo científico publicado en 2008
Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.
artículo científico publicado en 2017
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results
artículo científico publicado en 2012
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
artículo científico publicado en 2012
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens
artículo científico publicado en 2009
Therapy-related myelofibrosis does not appear to exist
scientific article published on 26 May 2017
Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia
⬇️
artículo científico publicado el 1 de agosto de 1997
Third-generation tyrosine kinase inhibitors and beyond
scientific article published on October 2010
Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?
artículo científico publicado en 1999
Time to response and survival in hypomethylating agent-treated acute myeloid leukemia
artículo científico publicado en 2017
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients
scientific article published on 14 July 2020
Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia
artículo científico
Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review
artículo científico
Towards a cure for chronic myeloid leukemia: are we there yet?
artículo científico publicado en 2010
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis
scientific article published on 21 September 2020
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
artículo científico publicado en 2017
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib
artículo científico publicado en 2011
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
artículo científico publicado en 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside
artículo científico publicado en 2003
Treatment of Relapsed/Refractory Acute Myeloid Leukemia
artículo científico publicado en 2017
Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine
artículo científico publicado en 1997
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
artículo científico publicado en 2002
Treatment options for chronic myeloid leukemia
artículo científico
Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study
scientific article published on 13 August 2019
Treatment selection after imatinib resistance in chronic myeloid leukemia
artículo científico publicado en 2009
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
scientific article published on 14 June 2019
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations
artículo científico publicado en 2014
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
artículo científico publicado en 2015
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
scientific article published on 10 December 2018
Treatment-free remission in chronic myeloid leukemia
artículo científico publicado en 2019
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors
artículo científico publicado en 2018
Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.
artículo científico publicado en 2012
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome
artículo científico publicado en 2006
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells
artículo científico publicado en 2009
Troxacitabine activity in extramedullary myeloid leukemia
artículo científico publicado en 2002
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation
artículo científico publicado en 2004
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
artículo científico publicado en 2001
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
artículo científico publicado en 2012
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study
artículo científico publicado en 2013
Tyrosine Kinase Inhibitor Interruptions, Discontinuations and Switching in Patients with Chronic-Phase Chronic Myeloid Leukemia in Routine Clinical Practice: SIMPLICITY
artículo científico publicado en 2018
Tyrosine Kinase Inhibitor-associated Fibrothorax
scientific article published on 01 June 2019
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia
artículo científico publicado en 2013
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
artículo científico publicado en 2009
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase
artículo científico publicado en 2013
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
artículo científico publicado en 2007
Tyrosine kinase inhibitors in acute and chronic leukemias
artículo científico
Tyrosine kinase inhibitors: the first decade
artículo científico publicado en 2010
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia
artículo científico publicado en 1999
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia
scientific article published on 31 May 2019
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome
artículo científico publicado en 2007
Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy
artículo científico publicado en 2002
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience
artículo científico publicado en 2003
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm
artículo científico
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes
scientific article published on 06 December 2018
Value of oligonucleotide-based array comparative genomic hybridization for diagnosis of acute promyelocytic leukemia in a patient negative for t(15;17)(q24.1;q21.2)/promyelocytic leukemia-retinoic acid receptor, alpha by conventional cytogenetics an
artículo científico publicado en 2013
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
artículo científico publicado en 2012
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
artículo científico publicado en 2017
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
artículo científico publicado en 2015
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation
artículo científico publicado en 2008
del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia
artículo científico publicado en 2009
inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.
artículo científico publicado en 2005
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts
artículo científico publicado en 2010
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy
artículo científico publicado en 2006